Chiron, Corp.
Chiron, Corp., a leading player in the biotechnology sector, is headquartered in the United States and operates extensively across North America and Europe. Founded in the early 2000s, the company has achieved significant milestones, including advancements in therapeutic solutions and innovative drug development.
Chiron, Corp. specialises in biopharmaceuticals, focusing on unique treatments for rare diseases and complex health conditions. Their core products are distinguished by cutting-edge research and a commitment to improving patient outcomes.
With a strong market position, Chiron, Corp. has garnered recognition for its contributions to the industry, including partnerships with major healthcare institutions and a robust pipeline of promising therapies. The company continues to push the boundaries of science, making a meaningful impact in the lives of patients worldwide.
+62 vs industry average
Chiron, Corp.’s score of 100 is higher than 100% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Part of the Sustainability team at Chiron, Corp.?
- Control how your company's emission story is told
- Respond to customers efficiently
- See who's viewing your profile
Industry Intensity
Pharmaceutical Preparation Manufacturing has below-average carbon intensity
Industry performance
The Pharmaceutical Preparation Manufacturing industry has increased its overall emissions by 132% since 0
Reported emissions
No reported emissions data is available for Chiron, Corp. yet.
Chiron, Corp.'s reported carbon emissions
Chiron, Corp., headquartered in the US, currently does not report specific carbon emissions data, as no emissions figures are available. However, the company is part of a corporate family relationship with Novartis AG, from which it inherits climate commitments and initiatives.
Chiron's climate strategy is aligned with Novartis AG's sustainability goals, which include various initiatives such as the Science Based Targets initiative (SBTi), CDP, RE100, and the Climate Pledge. These initiatives aim to drive significant reductions in greenhouse gas emissions across the organisation.
As a merged entity, Chiron benefits from Novartis AG's established climate commitments, although specific reduction targets for Chiron itself have not been disclosed. The cascading of data and initiatives from Novartis AG indicates a commitment to addressing climate change, although the exact scope of emissions (Scope 1, 2, or 3) and specific reduction achievements remain unspecified.
In summary, while Chiron, Corp. does not provide direct emissions data, it is positioned within a framework of robust climate commitments inherited from Novartis AG, reflecting a broader industry trend towards sustainability and emissions reduction.
Unlock detailed emission data
Access structured emission data, company specific factors and auditable source documents
Chiron, Corp.’s Climate Goals (2030 & 2050)
No climate goals have been disclosed for Chiron, Corp. yet.
Scope 3 top emissions categories
No scope 3 category breakdown has been disclosed yet.
Climate initiatives
Science Based Targets Initiative
Inherited from Novartis AG
Carbon Disclosure Project
Inherited from Novartis AG
The Climate Pledge
Inherited from Novartis AG
UN Global Compact Climate Champions initiative
RE 100
Inherited from Novartis AG
Climate Action 100
Emissions comparison with industry peers
View similar organisations
Usage policy
You’re welcome to quote or reference data from this page, but please include a visible link back to this URL. Bulk collection, resale, or redistribution of data from multiple profiles is not permitted.
See our License Agreement for more details.
Where does DitchCarbondata come from?
Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers
Learn moreCurious to see your top suppliers emissions?
Book a demo for a pilot project